Arcellx
Acquired
Reimagining cell therapy.
- Employees
- 51–200
- Business Model
- B2B
- Website
- arcellx.com
- Total Funding
- $375.0M
- Valuation
- $7.8BFeb 2026
- Last Round
- $25.0M SeedJan 2024
About
Founded in 2015, Arcellx engineers innovative immunotherapies using its proprietary ARC-SparX platform to develop safer, more effective cell therapies. The company focuses on hematologic cancers and autoimmune conditions, with programs in multiple myeloma and other indications.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account